PE20070618A1 - Composicion farmaceutica que contiene rosiglitazona en el tratamiento de alzheimer - Google Patents
Composicion farmaceutica que contiene rosiglitazona en el tratamiento de alzheimerInfo
- Publication number
- PE20070618A1 PE20070618A1 PE2006001145A PE2006001145A PE20070618A1 PE 20070618 A1 PE20070618 A1 PE 20070618A1 PE 2006001145 A PE2006001145 A PE 2006001145A PE 2006001145 A PE2006001145 A PE 2006001145A PE 20070618 A1 PE20070618 A1 PE 20070618A1
- Authority
- PE
- Peru
- Prior art keywords
- treatment
- pharmaceutical composition
- alzheimer
- composition containing
- contact
- Prior art date
Links
- YASAKCUCGLMORW-UHFFFAOYSA-N Rosiglitazone Chemical compound C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O YASAKCUCGLMORW-UHFFFAOYSA-N 0.000 title abstract 4
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 229960004586 rosiglitazone Drugs 0.000 title abstract 2
- 239000012736 aqueous medium Substances 0.000 abstract 2
- 230000001149 cognitive effect Effects 0.000 abstract 2
- ADEBPBSSDYVVLD-UHFFFAOYSA-N donepezil Chemical compound O=C1C=2C=C(OC)C(OC)=CC=2CC1CC(CC1)CCN1CC1=CC=CC=C1 ADEBPBSSDYVVLD-UHFFFAOYSA-N 0.000 abstract 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 229960003530 donepezil Drugs 0.000 abstract 1
- 239000002702 enteric coating Substances 0.000 abstract 1
- 238000009505 enteric coating Methods 0.000 abstract 1
- 239000012729 immediate-release (IR) formulation Substances 0.000 abstract 1
- 239000008101 lactose Substances 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A61K9/2846—Poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2821—Alzheimer
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biotechnology (AREA)
- Endocrinology (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US71935305P | 2005-09-22 | 2005-09-22 | |
| US72737705P | 2005-10-17 | 2005-10-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20070618A1 true PE20070618A1 (es) | 2007-07-04 |
Family
ID=37876831
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2006001145A PE20070618A1 (es) | 2005-09-22 | 2006-09-21 | Composicion farmaceutica que contiene rosiglitazona en el tratamiento de alzheimer |
| PE2006001143A PE20070976A1 (es) | 2005-09-22 | 2006-09-21 | Metodo de mejora de la funcion cognitiva |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2006001143A PE20070976A1 (es) | 2005-09-22 | 2006-09-21 | Metodo de mejora de la funcion cognitiva |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US20080262047A1 (enExample) |
| EP (2) | EP1940403A2 (enExample) |
| JP (2) | JP2009508960A (enExample) |
| KR (2) | KR20080058413A (enExample) |
| AR (2) | AR055649A1 (enExample) |
| AU (2) | AU2006295007A1 (enExample) |
| BR (2) | BRPI0616192A2 (enExample) |
| CA (2) | CA2623204A1 (enExample) |
| CR (2) | CR9848A (enExample) |
| EA (2) | EA200800879A1 (enExample) |
| IL (2) | IL190224A0 (enExample) |
| MA (2) | MA29871B1 (enExample) |
| NO (2) | NO20081843L (enExample) |
| PE (2) | PE20070618A1 (enExample) |
| TW (2) | TW200803896A (enExample) |
| WO (2) | WO2007038115A2 (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2663347A1 (en) * | 2006-09-19 | 2008-03-27 | Braincells, Inc. | Ppar mediated modulation of neurogenesis |
| IL187159A0 (en) * | 2007-07-03 | 2009-02-11 | Gur Megiddo | Use of metadoxine in relief of alcohol intoxication |
| WO2009043593A1 (en) * | 2007-10-05 | 2009-04-09 | Merz Pharma Gmbh & Co. Kgaa | Combination therapy using memantine and glitazones |
| EP2085120A1 (en) * | 2008-02-01 | 2009-08-05 | Merz Pharma GmbH & Co. KGaA | The use of substances for the treatment of central or peripheral insulin receptor impairment and insulin resistance |
| US8846315B2 (en) | 2008-08-12 | 2014-09-30 | Zinfandel Pharmaceuticals, Inc. | Disease risk factors and methods of use |
| NZ710443A (en) | 2008-08-12 | 2019-03-29 | Zinfandel Pharmaceuticals Inc | Method of identifying disease risk factors |
| WO2010068750A2 (en) * | 2008-12-11 | 2010-06-17 | Board Of Trustees Of Leland Stanford Junior University | Compositons and method for treatment of mood and cognitive impairments |
| BRPI1015231A2 (pt) * | 2009-06-25 | 2018-02-20 | Alcobra Ltd | método para tratamento, suavização de sintomas, alívio, melhoria e prevenção de uma doença, distúrbio ou condição cognitiva |
| US20100178307A1 (en) * | 2010-01-13 | 2010-07-15 | Jianye Wen | Transdermal anti-dementia active agent formulations and methods for using the same |
| WO2012053016A1 (en) * | 2010-10-22 | 2012-04-26 | Cadila Healthcare Limited | Sustained release pharmaceutical compositions of donepezil |
| MX358594B (es) * | 2011-01-10 | 2018-08-27 | Zinfandel Pharmaceuticals Inc | Factores de riesgo de enfermedad y métodos de uso. |
| AU2012205798B2 (en) | 2011-01-10 | 2016-02-25 | Takeda Pharmaceutical Company Limited | Methods and drug products for treating Alzheimer's disease |
| US9907789B2 (en) | 2011-10-21 | 2018-03-06 | Takeda Pharmaceutical Company Limited | Sustained-release preparation |
| US20140294724A1 (en) * | 2011-10-24 | 2014-10-02 | Intellect Neurosciences, Inc. | Compositions and methods for treatment of proteinopathies |
| WO2014171542A1 (ja) * | 2013-04-19 | 2014-10-23 | 武田薬品工業株式会社 | 放出制御製剤 |
| AU2017301596A1 (en) * | 2016-07-26 | 2019-02-07 | Ausio Pharmaceuticals, Llc | Methods of diagnosing and treating Alzheimer's disease with S-equol |
| US20180153859A1 (en) * | 2016-12-02 | 2018-06-07 | T3D Therapeutics, Inc. | Methods of treating or preventing cognitive impairment using indane acetic acid derivatives based on apoe4 genotype |
| KR102142026B1 (ko) * | 2017-05-31 | 2020-08-06 | 주식회사 대웅제약 | 방출제어가 용이한 서방성 약물 미립자의 제조방법 |
| KR102224918B1 (ko) | 2018-03-20 | 2021-03-09 | (주)인벤티지랩 | 도네페질 및 메만틴을 포함하는 인지 장애 관련 질병의 예방 또는 치료용 약학적 복합 조성물 및 이의 제조 방법 |
| US12303604B1 (en) | 2024-10-16 | 2025-05-20 | Currax Pharmaceuticals Llc | Pharmaceutical formulations comprising naltrexone and/or bupropion |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FI951701L (fi) * | 1992-10-13 | 1995-04-10 | Univ Duke | Menetelmät Alzheimerin taudin tunnistamiseksi |
| US6191154B1 (en) * | 1998-11-27 | 2001-02-20 | Case Western Reserve University | Compositions and methods for the treatment of Alzheimer's disease, central nervous system injury, and inflammatory diseases |
| DE69942672D1 (de) * | 1998-12-17 | 2010-09-23 | Mindset Biopharmaceuticals Usa | Verbesserung der geistigen fähigkeiten durch die steigerung der insulin-empfindlichkeit des gehirns |
| WO2005074917A1 (en) * | 2004-01-30 | 2005-08-18 | Axonyx, Inc. | Methods for treatment of complications of diabetes |
-
2006
- 2006-09-20 EP EP06803887A patent/EP1940403A2/en not_active Withdrawn
- 2006-09-20 KR KR1020087009286A patent/KR20080058413A/ko not_active Withdrawn
- 2006-09-20 CA CA002623204A patent/CA2623204A1/en not_active Abandoned
- 2006-09-20 KR KR1020087009295A patent/KR20080056731A/ko not_active Withdrawn
- 2006-09-20 AU AU2006295007A patent/AU2006295007A1/en not_active Abandoned
- 2006-09-20 CA CA002623210A patent/CA2623210A1/en not_active Abandoned
- 2006-09-20 BR BRPI0616192-8A patent/BRPI0616192A2/pt not_active Application Discontinuation
- 2006-09-20 WO PCT/US2006/036603 patent/WO2007038115A2/en not_active Ceased
- 2006-09-20 EA EA200800879A patent/EA200800879A1/ru unknown
- 2006-09-20 JP JP2008532341A patent/JP2009508960A/ja active Pending
- 2006-09-20 US US12/067,374 patent/US20080262047A1/en not_active Abandoned
- 2006-09-20 US US12/067,382 patent/US20080226719A1/en not_active Abandoned
- 2006-09-20 AU AU2006295010A patent/AU2006295010A1/en not_active Abandoned
- 2006-09-20 JP JP2008532338A patent/JP2009508959A/ja active Pending
- 2006-09-20 TW TW095134699A patent/TW200803896A/zh unknown
- 2006-09-20 TW TW095134700A patent/TW200803851A/zh unknown
- 2006-09-20 BR BRPI0616100-6A patent/BRPI0616100A2/pt not_active Application Discontinuation
- 2006-09-20 WO PCT/US2006/036597 patent/WO2007038112A2/en not_active Ceased
- 2006-09-20 EP EP06815011A patent/EP1926488A2/en not_active Withdrawn
- 2006-09-20 EA EA200800880A patent/EA200800880A1/ru unknown
- 2006-09-21 PE PE2006001145A patent/PE20070618A1/es not_active Application Discontinuation
- 2006-09-21 PE PE2006001143A patent/PE20070976A1/es not_active Application Discontinuation
- 2006-09-25 AR ARP060104149A patent/AR055649A1/es unknown
- 2006-09-25 AR ARP060104148A patent/AR056527A1/es unknown
-
2008
- 2008-03-17 IL IL190224A patent/IL190224A0/en unknown
- 2008-03-17 IL IL190217A patent/IL190217A0/en unknown
- 2008-03-28 CR CR9848A patent/CR9848A/es not_active Application Discontinuation
- 2008-03-28 CR CR9849A patent/CR9849A/es not_active Application Discontinuation
- 2008-04-15 MA MA30849A patent/MA29871B1/fr unknown
- 2008-04-15 MA MA30850A patent/MA29872B1/fr unknown
- 2008-04-16 NO NO20081843A patent/NO20081843L/no not_active Application Discontinuation
- 2008-04-16 NO NO20081847A patent/NO20081847L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| BRPI0616192A2 (pt) | 2011-06-14 |
| CR9848A (es) | 2008-06-18 |
| AU2006295007A1 (en) | 2007-04-05 |
| WO2007038112A2 (en) | 2007-04-05 |
| EP1940403A2 (en) | 2008-07-09 |
| JP2009508960A (ja) | 2009-03-05 |
| NO20081847L (no) | 2008-06-18 |
| BRPI0616100A2 (pt) | 2011-06-07 |
| US20080226719A1 (en) | 2008-09-18 |
| AR056527A1 (es) | 2007-10-10 |
| KR20080056731A (ko) | 2008-06-23 |
| KR20080058413A (ko) | 2008-06-25 |
| TW200803896A (en) | 2008-01-16 |
| EA200800880A1 (ru) | 2009-02-27 |
| IL190217A0 (en) | 2008-11-03 |
| MA29872B1 (fr) | 2008-10-03 |
| JP2009508959A (ja) | 2009-03-05 |
| CA2623210A1 (en) | 2007-04-05 |
| EA200800879A1 (ru) | 2008-10-30 |
| CR9849A (es) | 2008-05-21 |
| AR055649A1 (es) | 2007-08-29 |
| MA29871B1 (fr) | 2008-10-03 |
| US20080262047A1 (en) | 2008-10-23 |
| CA2623204A1 (en) | 2007-04-05 |
| WO2007038112A3 (en) | 2007-12-06 |
| PE20070976A1 (es) | 2007-12-05 |
| EP1926488A2 (en) | 2008-06-04 |
| NO20081843L (no) | 2008-06-16 |
| TW200803851A (en) | 2008-01-16 |
| IL190224A0 (en) | 2008-11-03 |
| WO2007038115A2 (en) | 2007-04-05 |
| AU2006295010A1 (en) | 2007-04-05 |
| WO2007038115A3 (en) | 2007-12-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20070618A1 (es) | Composicion farmaceutica que contiene rosiglitazona en el tratamiento de alzheimer | |
| CY1120961T1 (el) | Δοσολογικες μορφες απο του στοματος που περιλαμβανουν αντιαιμοπεταλιακο παραγοντα και αναστολεα οξεος | |
| CL2007002867A1 (es) | Compuestos derivados de 2-(bencimidazolil)purina, inhibidores de janus quinasa 3; composicion farmaceutica que los contiene; y su uso para tratar enfermedades autoinmune, inflamatorias, cardiovasculares, rechazo de implante, entre otras. | |
| CL2007002121A1 (es) | Compuestos derivados de pirazoles, activadores de glucoquinasa; proceso de preparacion de dichos compuestos; composicion farmaceutica que comprende dichos compuestos; y uso para el tratamiento de enfermedades y/o trastornos metabolicos, tal como diab | |
| WO2008011335A3 (en) | Metal binding compounds, metal binding compositions, and their uses | |
| CL2018001420A1 (es) | Tratamiento de trastornos cognitivos con (r)-7-cloro-n-(quinuclidin-3-il)benzo[b]tiofeno-2-carboxamida y sales farmacéuticamente aceptables de la misma. (divisional solicitud 201701853) | |
| MY152283A (en) | Polo-like kinase inhibitirs | |
| CL2007000789A1 (es) | Compuestos derivados de malonamida, inhibidores de la gamma-secretasa; proceso de preparacion; composicion farmaceutica; y su uso en el tratamiento de la enfermedad de alzheimer. | |
| TN2009000249A1 (en) | Mapk/erk kinase inhibitors | |
| NO20081592L (no) | Dipeptidylpeptidaseinhibitorer for behandling av diabetes | |
| CL2009000316A1 (es) | Compuestos derivados de urea de benzomorfanos y sus sales, inhibidores de la enzima 11-beta-hidroxiesteroide deshidrogenasa; procedimiento de preparacion; composicion farmaceutica; y uso para el tratamiento o prevencion de trastornos metabolicos. | |
| PE20081372A1 (es) | COMPOSICION FARMACEUTICA QUE COMPRENDE 2-[4-(7-ETIL-5H-PIRROLO[2,3-b]PIRAZIN-6-IL)-FENIL]-PROPAN-2-OL COMO INHIBIDOR DE QUINASA | |
| WO2008115890A3 (en) | Mapk/erk kinase inhibitors | |
| BRPI0719497A2 (pt) | "composição, processo de preparação de uma composição, usos de uma composição e uso coméstico de uma composição" | |
| CL2008003472A1 (es) | Compuestos derivados de 5-[3,3,3-trifluoro-2-hidroxi-1-arilpropil)amino]-1h-quinolin-2-ona, proceso para la preparacion de los mismos, compuestos intermediarios, composicion farmaceutica que comprende dicho compuesto; combinacion farmaceutica, y sus usos en el tratamiento de enfermedades inflamatorias. | |
| MY140514A (en) | Triazolopyridine derivatives as inhibitors of lipases and phospholipases | |
| CL2007003672A1 (es) | Compuestos derivados de heteroaril-pirrolidinil-cetona y heteroaril-piperidinil-cetona; composicion farmaceutica; y uso en el tratamiento de la depresion y ansiedad. | |
| AR050717A1 (es) | Composiciones farmaceuticas | |
| UA98299C2 (ru) | Новая лекарственная форма рацекадотрила | |
| DOP2006000235A (es) | Derivados de acidos dicarboxilicos y su uso | |
| CL2007001838A1 (es) | Compuestos derivados de 4-oxoquinolina; composicion farmaceutica; y uso del compuesto para la produccion de un agente anti-vih. | |
| CL2007002619A1 (es) | Compuestos derivados de 3-aza-biciclo[4.1.0]heptano; composicion farmaceutica; y uso en el tratamiento de la depresion. | |
| ATE390138T1 (de) | Dipyridamol enthaltende zusammensetzungen mit verlängerter freisetzung und verfahren zu deren herstellung | |
| CL2008000454A1 (es) | Un granulo que comprende un nucleo que comprende quetiapina y un agente aglutinante y una capa de recubrimiento que comprende un agente lubricante; procedimiento de preparacion; y composicion farmaceutica. | |
| CL2007002243A1 (es) | Composicion de polietileno de alta densidad que comprende un polietileno de alta densidad, polietilenglicol y octadecil 3-(3,5-di-tert-butil-4-hidroxifenil) propianato; proceso para hacer una composicion de polietileno de alta densidad; articulo; apa |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |